SAGE-217 is primarily utilized in the field of psychiatry and neurology for its potential therapeutic effects on mood disorders. It is being investigated as a treatment for major depressive disorder (MDD) and postpartum depression (PPD) due to its ability to modulate GABA receptors, which play a crucial role in regulating brain activity and mood. Clinical trials have shown promise in improving symptoms of depression, particularly in patients who have not responded well to traditional antidepressants. Additionally, its rapid onset of action makes it a potential candidate for addressing acute depressive episodes, offering hope for faster relief compared to conventional treatments. Research is ongoing to explore its efficacy and safety in broader psychiatric applications.